Medico Intercontinental Limited has filed its quarterly confirmation certificate with BSE Limited, fulfilling regulatory compliance requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated April 04, 2026, covers the company's dematerialization activities for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted the mandatory Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 to BSE Limited. Managing Director Samir D Shah signed the filing letter, which was addressed to the Listing Compliances department at BSE's P.J. Towers office in Mumbai.

Registrar Confirmation

Purva Sharegistry (India) Pvt. Ltd., serving as the company's registrar and transfer agent, provided the confirmation certificate dated April 01, 2026. The SEBI-registered entity (Registration No. INR000001112) confirmed compliance with dematerialization procedures and timelines as mandated under the regulations.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation certificate. The registrar confirmed that all security certificates received for dematerialization were properly processed, with appropriate entries made in the register of members within prescribed timelines.

Dematerialization Activity Report

The quarterly report revealed no dematerialization activity during the period from January 01, 2026 to March 31, 2026. The detailed breakdown shows:

Company Information

Medico Intercontinental Limited operates with CIN L24100GJ1984PLC111413 and maintains its registered office at Aditraj Arcade, Satellite, Ahmedabad. The company's shares trade on BSE under scrip code 539938 with the identifier MIL.

The filing demonstrates the company's adherence to SEBI's quarterly reporting requirements for depositories and participants, ensuring transparency in share dematerialization processes and maintaining compliance with securities market regulations.

Medico Intercontinental Limited has delivered a strong financial performance for the third quarter of FY26, showcasing consistent growth across key metrics. The pharmaceutical company's latest results demonstrate resilience and operational efficiency in a competitive market environment.

Financial Performance Overview

The company's quarterly performance reflects steady business momentum with improved profitability metrics. Revenue growth was supported by robust operational activities, while cost management initiatives contributed to enhanced bottom-line performance.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Medico Intercontinental faced challenges with revenue declining compared to the previous year. The extended period results show the company navigating market headwinds while maintaining operational focus.

Operational Highlights

The company's operational structure remained focused on its core pharmaceutical business segment. During Q3FY26, Medico Intercontinental operated as a single segment entity, maintaining its strategic focus on pharmaceutical operations. The company's total expenses stood at ₹1270.10 lakhs in Q3FY26 compared to ₹1084.96 lakhs in the corresponding previous quarter.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2026. The results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have received an unmodified opinion from statutory auditors. The company maintains a paid-up equity share capital of ₹1000.00 lakhs with shares having a face value of ₹10 each.

Tax Management and Regulatory Compliance

Medico Intercontinental continues to evaluate tax optimization strategies under the current regulatory framework. The company has maintained its approach with existing income tax rates while assessing options available under section 115BAA of the Income Tax Act, 1961, as per the Taxation Laws (Amendment) Ordinance, 2019. Current tax expense for Q3FY26 stood at ₹22.61 lakhs compared to ₹15.53 lakhs in Q3FY25.